Citations 2
Call to action—Pediatric MASLD requires immediate attention to curb health crisis
Hartmann, Phillipp , Hassan, Sara , Kehar, Mohit , Mysore, Krupa R. , Mauney, Erin E. , Nonga, Dieudonne, Karjoo, Sara , Sood, Shilpa , Tou, Andrea , Brichta, Christine, Herdes, Rachel E. , Garner, Donna, Rinella, Mary E., Noureddin, Mazen , Younossi, Zobair M. , Kohut, Taisa , Ramirez, Charina M. , Xanthakos, Stavra A. , Vos, Miriam B., Ibrahim, Samar H. , Panganiban, Jennifer , Rinella, Mary E. , Mysore, Krupa R , Karjoo, Sara , Sood, Shilpa , Ibrahim, Samar H , Rinella, Mary , Mouzaki, Marialena , Nonga, Dieudonne , Brichta, Christine E. , Pai, Nikhil , Allen, Alina M. , Sanyal, Arun J. , Kohli, Rohit , Schwimmer, Jeffrey B.
Hepatology | June 23, 2025 | Volume: 82 | Issue: 5 | Pages: 1341-1351
Pediatric metabolic dysfunction–associated steatotic liver disease (MASLD) has become more prevalent on a global scale over the last decades and is associated with significant comorbidities in childhood and a 40-fold higher risk of early mortality in young adulthood. MASLD has now become the leading indication for liver transplantation in young adults in the United States. However, pediatric MASLD is still perceived as an indolent condition by many patients, families, and clinicians. In this Call to Action, we aim to raise awareness of pediatric MASLD as a public health crisis. Herein, we describe insufficient screening and disease staging practices, and a lack of accurate non-invasive tests and effective pharmacotherapy, both stemming from a paucity of multicenter clinical trials in pediatric MASLD. We provide clear steps to address this public health emergency by promoting awareness campaigns, educating and empowering patients and families, addressing barriers including access to care, nutritional and exercise support programs, establishing multidisciplinary care, launching community initiatives, and conducting clinical trials in pediatric MASLD for an age-based evaluation of novel diagnostic and therapeutic options. We conclude by highlighting the urgent need for comprehensive public health policies to control the tide of pediatric MASLD and call upon stakeholders to act now.
Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease
Nicholson, Maribeth R. , Alexander, Erin, Ballal, Sonia, Davidovics, Zev, Docktor, Michael , Dole, Michael , Gisser, Jonathan M., Goyal, Alka , Hourigan, Suchitra K. , Jensen, M. Kyle , Kaplan, Jess L. , Kelsen, Judith R. , Khanna, Sahil , Knackstedt, Elizabeth D , Lentine, Jennifer, Lewis, Jeffery D., Michail, Sonia , Mitchell, Paul D. , Patton, Tiffany , Queliza, Karen , Sidhu, Sarah , Solomon, Aliza , Suskind, David L. , Weatherly, Madison, Werlin, Steven L. , Zoeten, Edwin F. de , Kahn, Stacy A. , Group, North American Society of Pediatric Gastroenterology and Nutrition Faecal Microbiota Transplantation Special Interest, Aktay, Nur, Asbah, Imad, Bassett, Mikelle, Brumbaugh, David , Caicedo, Luis A. , Chawla, Anu, Conrad, Máire , Dykes, Chelly Dana, Grzywacz, Kelly, Gulati, Ajay, Gurram, Bhaskar , Hellman, Jenny, Kastl, Art, Mallon, Danny, Pai, Nikhil , Pasternak, Brad , Prozialeck, Josh, Reilly, Norelle R., Russell, George H., Singh, Namita , Small‐Harary, Lesley , Sood, Shilpa , Stumphy, Jessica, Sullivan, Jill M., Syed, Sabeen, Titgemeyer, Cebie, Townsend, Pete, Zheng, Yuhua , Suskind, David L , Alexander, Erin, Kellermayer, Richárd , Kennedy, Melissa A, Oliva‐Hemker, Maria , Group, North American Society of Pediatric Gastroenterology and Nutrition Faecal Microbiota Transplantation Special Interest, Bartlett, Mark, Caicedo, Luis, Gulati, Ajay, Patel, Ashish , Prozialeck, Joshua D. , Sood, Shilpa, Sullivan, Jill
Journal of Crohn's and Colitis | November 8, 2021 | Volume: 16 | Issue: 5 | Pages: 768-777
Abstract Background Children with inflammatory bowel disease [IBD] are disproportionally affected by recurrent Clostridioides difficile infection [rCDI]. Although faecal microbiota transplantation [FMT] has been used with good efficacy in adults with IBD, little is known about outcomes associated with FMT in paediatric IBD. Methods We performed a retrospective review of FMT at 20 paediatric centres in the USA from March 2012 to March 2020. Children with and without IBD were compared with determined differences in the efficacy of FMT for rCDI. In addition, children with IBD with and without a successful outcome were compared with determined predictors of success. Safety data and IBD-specific outcomes were obtained. Results A total of 396 paediatric patients, including 148 with IBD, were included. Children with IBD were no less likely to have a successful first FMT then the non-IBD affected cohort [76% vs 81%, p = 0.17]. Among children with IBD, patients were more likely to have a successful FMT if they received FMT with fresh stool [p = 0.03], were without diarrhoea prior to FMT [p = 0.03], or had a shorter time from rCDI diagnosis until FMT [p = 0.04]. Children with a failed FMT were more likely to have clinically active IBD post-FMT [p = 0.002] and 19 [13%] patients had an IBD-related hospitalisation in the 3-month follow-up. Conclusions Based on the findings from this large US multicentre cohort, the efficacy of FMT for the treatment of rCDI did not differ in children with IBD. Failed FMT among children with IBD was possibly related to the presence of clinically active IBD.